MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has reached a definitive agreement with MC2 Therapeutics to commercialize Wynzora® Cream in Canada through its subsidiary, Paladin Pharma Inc. This strategic move aims to provide a new treatment option for Canadians suffering from plaque psoriasis, pending Health Canada’s approval.
Livio Di Francesco, Vice President and General Manager of Paladin, expressed enthusiasm about the collaboration, stating, “We look forward to working with MC2 to make Wynzora® Cream available to Canadians who suffer from plaque psoriasis. If approved by Health Canada, Wynzora® Cream’s unique formulation and clinical profile will offer patients a new treatment option designed for convenience of use in daily routines.”
Wynzora® Cream, featuring a combination of calcipotriene and betamethasone dipropionate, has already been approved by the FDA in the United States since July 2020 and launched in Europe in February 2022. The cream’s innovative formulation aims to simplify daily treatment routines for patients by combining the efficacy of a dual-action therapy with user-friendly application.
Jesper J. Lange, Chief Executive Officer of MC2 Therapeutics, highlighted the significance of the partnership, saying, “Paladin has an experienced and dedicated team, and we’re pleased to work with them to introduce Wynzora® Cream in Canada. The agreement aligns with our strategy to make Wynzora® Cream available to as many patients suffering from plaque psoriasis as possible globally.”
This collaboration between Endo and MC2 Therapeutics marks a significant step towards expanding the availability of Wynzora® Cream, potentially enhancing the quality of life for those affected by plaque psoriasis in Canada. The partnership underscores both companies’ commitment to providing innovative and effective solutions for patients worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.